{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:09:28Z","timestamp":1758636568209,"version":"3.41.2"},"reference-count":28,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:p>There is increasing evidence supporting the use of corticotropin as an alternative treatment of refractory proteinuric glomerulopathies. The efficacy of short-acting corticotropin, however, remains unknown and was tested here in an adolescent with steroid-dependent nephrotic syndrome caused by minimal change disease. After developing Cushing syndrome and recently being afflicted with severe cellulitis, the patient was weaned off all immunosuppressants, including corticosteroids. This resulted in a relapse of generalized anasarca, associated with massive proteinuria and hypoalbuminemia. Subsequently, mono-therapy with short-acting animal-derived natural corticotropin was initiated and resulted in a rapid response, marked by substantial diuresis, reduction in body weight, and partial remission of proteinuria. Ten days later, the patient developed mild skin rash and subcutaneous nodules at injection sites. A relapse followed despite doubling the dose of corticotropin, consistent with delayed-onset resistance to treatment. Immunoblot-based antibody assay revealed de novo formation of antibodies in the patient\u2019s serum that were reactive to the natural corticotropin. In cultured melanoma cells known to express abundant melanocortin receptors, addition of the patient\u2019s serum strikingly mitigated dendritogenesis and cell signaling triggered by natural corticotropin, denoting neutralizing properties of the newly formed antibodies. Collectively, short-acting natural corticotropin seems effective in steroid-dependent nephrotic syndrome. De novo formation of neutralizing antibodies is likely responsible for acquired resistance to corticotropin therapy. The proof of concept protocols established in this study to examine the anticorticotropin neutralizing antibodies may aid in determining the cause of resistance to corticotropin therapy in future studies.<\/jats:p>","DOI":"10.1542\/peds.2016-2169","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T09:10:44Z","timestamp":1498209044000},"source":"Crossref","is-referenced-by-count":5,"title":["Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody"],"prefix":"10.1542","volume":"140","author":[{"given":"Pei","family":"Wang","sequence":"first","affiliation":[{"name":"Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;"},{"name":"Divisions of Kidney Disease and Hypertension, Rhode Island Hospital, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Tongbai County Hospital, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Brem","sequence":"additional","affiliation":[{"name":"Divisions of Kidney Disease and Hypertension, Rhode Island Hospital, and"},{"name":"Pediatric Nephrology, Hasbro Children\u2019s Hospital, Brown Medical School, Providence, Rhode Island; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangsuo","family":"Liu","sequence":"additional","affiliation":[{"name":"Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rujun","family":"Gong","sequence":"additional","affiliation":[{"name":"Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;"},{"name":"Divisions of Kidney Disease and Hypertension, Rhode Island Hospital, and"},{"name":"Pediatric Nephrology, Hasbro Children\u2019s Hospital, Brown Medical School, Providence, Rhode Island; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"issue":"8","key":"2021121102561646500_B1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2012.115","article-title":"Childhood nephrotic syndrome\u2014current and future therapies.","volume":"8","author":"Greenbaum","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2021121102561646500_B2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies.","volume":"8","author":"Gong","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2021121102561646500_B3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ackd.2013.09.004","article-title":"Leveraging melanocortin pathways to treat glomerular diseases.","volume":"21","author":"Gong","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2021121102561646500_B4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1749-6632.2009.04434.x","article-title":"Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of Robert Schwyzer: a thirty-year retrospective.","volume":"1163","author":"Dores","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2021121102561646500_B5","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1152\/ajpendo.00434.2002","article-title":"The melanocortin system.","volume":"284","author":"Gantz","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"2021121102561646500_B6","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1046\/j.1523-1755.1999.00675.x","article-title":"Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy.","volume":"56","author":"Berg","year":"1999","journal-title":"Kidney Int"},{"issue":"5","key":"2021121102561646500_B7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/ndt\/gfh110","article-title":"ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses.","volume":"19","author":"Berg","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2021121102561646500_B8","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2215\/CJN.02840313","article-title":"Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.","volume":"8","author":"Hogan","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021121102561646500_B9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/DDDT.S17521","article-title":"Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.","volume":"5","author":"Bomback","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2021121102561646500_B10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.","volume":"36","author":"Bomback","year":"2012","journal-title":"Am J Nephrol"},{"issue":"5","key":"2021121102561646500_B11","first-page":"250","article-title":"H.p. Acthar gel and cosyntropin review: clinical and financial implications.","volume":"34","author":"Gettig","year":"2009","journal-title":"P&T"},{"issue":"9","key":"2021121102561646500_B12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"8","key":"2021121102561646500_B13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"17","key":"2021121102561646500_B14","first-page":"1623","article-title":"An effective initial polytherapy for children with West syndrome.","volume":"8","author":"Jia","year":"2013","journal-title":"Neural Regen Res"},{"issue":"6","key":"2021121102561646500_B15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.30.6.589","article-title":"Development of antibodies during long-term therapy with corticotrophin in rheumatoid arthritis. I. Porcine ACTH.","volume":"30","author":"Glass","year":"1971","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2021121102561646500_B16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jcem-25-10-1361","article-title":"Immunologic studies of adrenocorticotropic hormone (ACTH): dissociation of biologic and immunologic activities.","volume":"25","author":"Imura","year":"1965","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2021121102561646500_B17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1172\/JCI105522","article-title":"ACTH antibodies in patients receiving depot porcine ACTH to hasten recovery from pituitary-adrenal suppression.","volume":"46","author":"Fleischer","year":"1967","journal-title":"J Clin Invest"},{"issue":"7491","key":"2021121102561646500_B18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0140-6736(67)92544-5","article-title":"Antibodies to corticotrophin and their relation to adrenal function in children receiving corticotrophin therapy.","volume":"1","author":"Landon","year":"1967","journal-title":"Lancet"},{"issue":"7589","key":"2021121102561646500_B19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(69)91040-X","article-title":"Effect of corticotorphin on skeletal maturation and linear growth in six patients with severe asthma.","volume":"1","author":"Norman","year":"1969","journal-title":"Lancet"},{"issue":"5049","key":"2021121102561646500_B20","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/211654a0","article-title":"Antibodies to synthetic corticotrophin.","volume":"211","author":"Felber","year":"1966","journal-title":"Nature"},{"issue":"18","key":"2021121102561646500_B21","doi-asserted-by":"crossref","first-page":"12564","DOI":"10.1074\/jbc.M800480200","article-title":"Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells.","volume":"283","author":"Smith","year":"2008","journal-title":"J Biol Chem"},{"issue":"2","key":"2021121102561646500_B22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1034\/j.1600-0749.2003.00022.x","article-title":"The cAMP signaling pathway has opposing effects on Rac and Rho in B16F10 cells: implications for dendrite formation in melanocytic cells.","volume":"16","author":"Scott","year":"2003","journal-title":"Pigment Cell Res"},{"issue":"2","key":"2021121102561646500_B23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2021121102561646500_B24","first-page":"15","article-title":"Immunogenicity of biological therapeutics: a hierarchy of concerns.","volume":"112","author":"Rosenberg","year":"2003","journal-title":"Dev Biol (Basel)"},{"issue":"49","key":"2021121102561646500_B25","first-page":"560","article-title":"The immunogenicity of therapeutic proteins.","volume":"9","author":"Schellekens","year":"2010","journal-title":"Discov Med"},{"issue":"6","key":"2021121102561646500_B26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/ard.30.6.593","article-title":"Development of antibodies during long-term therapy with corticotrophin in rheumatoid arthritis. II. Zinc tetracosactrin (Depot Synacthen).","volume":"30","author":"Glass","year":"1971","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2021121102561646500_B27","first-page":"l","article-title":"The production of antibodies to porcine corticotrophin and to Synacthen.","volume":"43","author":"Ratcliffe","year":"1969","journal-title":"J Endocrinol"},{"issue":"4","key":"2021121102561646500_B28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12795","article-title":"Spontaneous and tetracosactide-induced anti-ACTH antibodies in man.","volume":"84","author":"Gan","year":"2016","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2169\/910759\/peds_20162169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2169\/910759\/peds_20162169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T08:40:31Z","timestamp":1639212031000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/140\/1\/e20162169\/38028\/Acquired-Resistance-to-Corticotropin-Therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-2169","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2017,7,1]]},"article-number":"e20162169"}}